Latest Insider Transactions at Passage Bio, Inc. (PASG)
This section provides a real-time view of insider transactions for Passage Bio, Inc. (PASG). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Passage BIO, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Passage BIO, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2022
|
Monika Maria Toernsen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
May 04
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
303,500
+4.25%
|
$303,500
$1.94 P/Share
|
|
May 03
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
221,500
+3.28%
|
$221,500
$1.93 P/Share
|
|
Mar 21
2022
|
Bruce A Goldsmith CEO and President |
BUY
Open market or private purchase
|
Direct |
10,000
+38.49%
|
$30,000
$3.15 P/Share
|
|
Jan 20
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
369,100
+5.27%
|
$1,845,500
$5.42 P/Share
|
|
Jan 19
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
43,300
+0.69%
|
$216,500
$5.11 P/Share
|
|
Jan 18
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
114,700
+1.81%
|
$573,500
$5.46 P/Share
|
|
Jan 14
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,300
+0.17%
|
$51,500
$5.6 P/Share
|
|
Jan 13
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
41,800
+0.68%
|
$209,000
$5.52 P/Share
|
|
Jan 12
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.62%
|
$500,000
$5.65 P/Share
|
|
Jan 11
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,200
+0.14%
|
$41,000
$5.53 P/Share
|
|
Dec 08
2021
|
Jill M. Quigley Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
71,975
+16.33%
|
$0
$0.23 P/Share
|
|
May 21
2021
|
Bruce A Goldsmith CEO and President |
BUY
Open market or private purchase
|
Direct |
2,000
+25.05%
|
$26,000
$13.12 P/Share
|
|
May 21
2021
|
Richard Steven Morris Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,171
+28.47%
|
$28,223
$13.82 P/Share
|
|
Mar 15
2021
|
Gary Romano Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-91.92%
|
$210,000
$21.41 P/Share
|
|
Mar 15
2021
|
Gary Romano Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$80,000
$8.07 P/Share
|
|
Jan 20
2021
|
Jill M. Quigley Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,300
-0.44%
|
$39,000
$30.01 P/Share
|
|
Jan 14
2021
|
Jill M. Quigley Chief Operating Officer |
BUY
Open market or private sale
|
Direct |
16,298
+5.21%
|
$488,940
$30.1 P/Share
|
|
Mar 03
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
5,574,023
+25.16%
|
-
|
|
Feb 28
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
373,300
+50.0%
|
$6,719,400
$18.0 P/Share
|